SCHEMBL6491103

SCHEMBL6491103

CC(C(=O)O)c1cccc(F)c1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.51
CES1 P23141 2/20 0.51
PTGS2 P35354 8/20 0.47
BCHE P06276 1/20 0.45
CXCL8 P10145 1/20 0.45
PTGS1 P23219 7/20 0.44
AKR1C3 P42330 5/20 0.44
AKR1C2 P52895 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
FABP2 P12104 1/20 0.44
TSHR P16473 1/20 0.44
AKR1C4 P17516 1/20 0.44
ADRA2B P18089 1/20 0.44
CHRM3 P20309 1/20 0.44
HTR2C P28335 1/20 0.44
DRD3 P35462 1/20 0.44
AKR1C1 Q04828 1/20 0.44
SLC22A6 Q4U2R8 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1261293 0.86 PTGS2 (0.46) PTGS2CXCL8PTGS1AKR1C3AKR1C2
SCHEMBL8142507 0.86 HIF1A (0.50) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL31415015 0.86 HIF1A (0.50) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL824969 0.86 HIF1A (0.50) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL8142511 0.86 HIF1A (0.50) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL31117047 0.86 HIF1A (0.50) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL4070595 0.85 ADRA2B (0.47) CES2CES1PTGS2CXCL8PTGS1
SCHEMBL195340 0.84 CES2 (0.49) CES2CES1PTGS2PTGS1AKR1C3
SCHEMBL287453 0.83 AKR1C3 (0.44) PTGS2CXCL8PTGS1AKR1C3AKR1C2
SCHEMBL10687309 0.83 PTGS2 (0.44) CES2CES1PTGS2CXCL8PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955244-A Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex 延安大学 2024-11-15 CN disclosed
EP-4126888-A1 COMPOUNDS USEFUL IN HIV THERAPY VIIV Healthcare Company (US) 2023-02-08 EP disclosed
WO-2021194828-A1 COMPOUNDS USEFUL IN HIV THERAPY VIIV HEALTHCARE COMPANY (US) 2021-09-30 WO disclosed
US-6972296-B2 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors ENCYSIVE PHARMACEUTICALS INC. (US) 2005-12-06 US disclosed